Insider Trading Alert - SPH, MSON And RSYS Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 19, 2015, 82 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $145.00 to $4,138,406.10.

Highlighted Stocks Traded by Insiders:

Suburban Propane Partners (SPH) - FREE Research Report

Keating Michael M, who is Senior Vice President at Suburban Propane Partners, sold 5,402 shares at $44.93 on Feb. 19, 2015. Following this transaction, the Senior Vice President owned 40,933 shares meaning that the stake was reduced by 11.66% with the 5,402-share transaction.

The shares most recently traded at $44.87, down $0.06, or 0.13% since the insider transaction. Historical insider transactions for Suburban Propane Partners go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 5,950
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 20,176
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 26,356

The average volume for Suburban Propane Partners has been 172,800 shares per day over the past 30 days. Suburban Propane Partners has a market cap of $2.7 billion and is part of the utilities sector and utilities industry. Shares are up 3.68% year-to-date as of the close of trading on Thursday.

Suburban Propane Partners, L.P., through its subsidiaries, engages in the retail marketing and distribution of propane, fuel oil, and refined fuels. The stock currently has a dividend yield of 7.72%. The company has a P/E ratio of 30.0. Currently, there is 1 analyst who rates Suburban Propane Partners a buy, 1 analyst rates it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SPH - FREE

TheStreet Quant Ratings rates Suburban Propane Partners as a buy. The company's strengths can be seen in multiple areas, such as its good cash flow from operations, notable return on equity and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Suburban Propane Partners Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Misonix (MSON) - FREE Research Report

Alliger Howard, who is Shareholder at Misonix, bought 15,000 shares at $5.87 on Feb. 19, 2015. Following this transaction, the Shareholder owned 73,900 shares meaning that the stake was boosted by 25.47% with the 15,000-share transaction.

Mcmanus Michael A Jr, who is President And Ceo at Misonix, sold 15,000 shares at $12.71 on Feb. 19, 2015. Following this transaction, the President And Ceo owned 351,017 shares meaning that the stake was reduced by 4.1% with the 15,000-share transaction.

Zaremba Richard A, who is Senior Vice President and CFO at Misonix, sold 9,000 shares at $13.26 on Feb. 19, 2015. Following this transaction, the Senior Vice President and CFO owned 120,326 shares meaning that the stake was reduced by 6.96% with the 9,000-share transaction.

The shares most recently traded at $12.25, down $1.01, or 8.21% since the insider transaction. Historical insider transactions for Misonix go as follows:

  • 4-Week # shares bought: 30,000
  • 4-Week # shares sold: 8,775
  • 12-Week # shares bought: 30,000
  • 12-Week # shares sold: 8,775
  • 24-Week # shares bought: 32,500
  • 24-Week # shares sold: 35,194

The average volume for Misonix has been 24,300 shares per day over the past 30 days. Misonix has a market cap of $95.8 million and is part of the health care sector and health services industry. Shares are down 1.29% year-to-date as of the close of trading on Thursday.

Misonix, Inc., a surgical device company, designs, develops, manufactures, and markets minimally invasive ultrasonic surgical device products for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical applications. The company has a P/E ratio of 33.9. Currently, there are no analysts who rate Misonix a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MSON - FREE

TheStreet Quant Ratings rates Misonix as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and impressive record of earnings per share growth. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Misonix Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Radisys (RSYS) - FREE Research Report

Steffes Lorene K, who is Director at Radisys, bought 5,000 shares at $2.18 on Feb. 19, 2015. Following this transaction, the Director owned 56,333 shares meaning that the stake was boosted by 9.74% with the 5,000-share transaction.

De Pesquidoux Hubert, who is Director at Radisys, bought 9,175 shares at $2.18 on Feb. 19, 2015. Following this transaction, the Director owned 38,174 shares meaning that the stake was boosted by 31.64% with the 9,175-share transaction.

The shares most recently traded at $2.25, up $0.07, or 3.12% since the insider transaction. Historical insider transactions for Radisys go as follows:

  • 4-Week # shares bought: 5,260
  • 4-Week # shares sold: 4,875
  • 12-Week # shares bought: 5,260
  • 12-Week # shares sold: 4,875
  • 24-Week # shares bought: 5,260
  • 24-Week # shares sold: 4,875

The average volume for Radisys has been 146,500 shares per day over the past 30 days. Radisys has a market cap of $80.3 million and is part of the technology sector and computer hardware industry. Shares are down 6.41% year-to-date as of the close of trading on Thursday.

Radisys Corporation operates as a provider of wireless infrastructure solutions in the telecom, aerospace, and defense markets. Currently, there is 1 analyst who rates Radisys a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on RSYS - FREE

TheStreet Quant Ratings rates Radisys as a sell. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself. Get the full Radisys Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Dow Set to Snap 8-Day Losing Streak as Stocks Recover, But Trade War Lingers

Dow Set to Snap 8-Day Losing Streak as Stocks Recover, But Trade War Lingers

Foxconn Chairman Terry Gou: US and China Are Waging a Global 'Tech War'

Foxconn Chairman Terry Gou: US and China Are Waging a Global 'Tech War'

Dow Sinks for Eighth Straight Session; Intel's CEO Departs -- ICYMI

Dow Sinks for Eighth Straight Session; Intel's CEO Departs -- ICYMI

Dow Logs Eighth Straight Drop as Stocks Slump

Dow Logs Eighth Straight Drop as Stocks Slump

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers